South America Continuous Glucose Monitoring Market Size, Share, Opportunities, And Trends By Application (Diabetic Patients, Critical Patients), By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care), And By Country - Forecasts From 2025 To 2030

Description

South America Continuous Glucose Monitoring Market Size:

The South America Continuous Glucose Monitoring Market is anticipated to expand at a high CAGR over the forecast period (2025-2030).

The South American Continuous Glucose Monitoring market is currently experiencing a fundamental shift in the standard of care for diabetes management. Historically reliant on self-monitoring of blood glucose (SMBG) via manual test strips, the regional market is rapidly adopting wearable biosensing technology. This evolution is propelled by the rising incidence of Type 1 and Type 2 diabetes across the continent, coupled with a growing clinical consensus that continuous data, rather than episodic readings, is essential for achieving glycemic targets and preventing costly long-term complications.

The market is characterized by a high degree of technological integration. CGM systems are no longer viewed as standalone hardware but as the "intelligence layer" of a broader digital health ecosystem. The proliferation of smartphone-enabled monitoring apps and the expansion of telehealth services in Brazil, Argentina, and Colombia have democratized access to real-time data for both patients and healthcare providers. This systemic digitalization is fostering a demand environment where accuracy, wear-time (extending up to 15.5 days with new-generation sensors), and ease of application are the primary competitive battlegrounds for multinational manufacturers.

South America Continuous Glucose Monitoring Market Analysis

• Growth Drivers

The primary growth driver is the surging regional prevalence of diabetes, which has reached critical levels due to urbanization and dietary shifts. This demographic reality creates a massive imperative for efficient monitoring solutions. Furthermore, technological interoperability acts as a powerful catalyst; the ability of CGM sensors to sync directly with automated insulin delivery (AID) systems and smartphone applications enhances patient compliance. As healthcare providers in South America increasingly adopt Remote Patient Monitoring (RPM) protocols, the demand for CGM devices that can transmit data to cloud-based clinical dashboards has intensified, allowing for proactive intervention and reducing the burden on overstretched public hospital systems.

• Challenges and Opportunities

Market penetration remains constrained by high out-of-pocket costs and limited public reimbursement in several South American territories. The recurring expense of sensor replacements often restricts long-term adherence among lower-income populations. However, this creates a significant opportunity for "Value-Based" product tiers. Manufacturers that introduce lower-cost, factory-calibrated sensors specifically tailored for the Type 2 non-intensive insulin market can capture a vast, underserved segment. Additionally, the recent streamlining of import regulations in Argentina and Brazil allows for faster market entry, providing an opportunity for companies to bypass historical bureaucratic bottlenecks and synchronize regional product launches with global cycles.

• Raw Material and Pricing Analysis

The CGM market is a hardware-intensive sector reliant on specialized biocompatible polymers and electrochemical sensors. The "sensor" component requires precious metal electrodes (typically platinum or gold) and glucose oxidase enzymes, the pricing of which is subject to global commodity fluctuations. In recent years, the medical device industry faced a steady annual increase in the producer price index for medical-grade plastics. In South America, currency volatility, particularly the fluctuation of the Brazilian Real and Argentine Peso against the US Dollar, directly impacts the retail pricing of these largely imported devices. To mitigate this, leading firms are exploring localized distribution hubs to optimize logistical costs.

• Supply Chain Analysis

The supply chain for the South American CGM market is highly centralized, with primary production hubs located in the United States and Europe. This creates a significant dependency on international air and sea freight, making the market vulnerable to global logistical disruptions. However, a move toward regionalized support and distribution is evident. Companies like Abbott and Medtronic utilize a "hub-and-spoke" model, using Brazil as a primary logistics gateway for the Mercosur region. The complexity of the supply chain is exacerbated by the need for cold-chain logistics for certain enzymatic sensor components, requiring sophisticated temperature-controlled warehousing to maintain product efficacy during the transition from manufacturing plants to local pharmacies and hospitals.

• Government Regulations

South America Continuous Glucose Monitoring Market Segment Analysis

• By Application: Diabetes Patients

The Diabetes Patients application segment remains the foundational pillar of the CGM market, accounting for the vast majority of regional revenue. This segment’s demand has shifted from Type 1 "intensive" users to a broader demographic including insulin-dependent Type 2 patients. This shift is driven by clinical evidence showing that CGM usage leads to a significant reduction in glycated hemoglobin (A1C) levels and fewer hypoglycemic events. In South America, the "Flash" glucose monitoring (FGM) technology, pioneered by Abbott’s FreeStyle Libre, has been a major disruptor due to its lower price point and "no-fingerstick" appeal. This has created a high-volume demand cycle where the convenience of a 14-day sensor outweighs the cost of traditional strips. Furthermore, the integration of AI-driven predictive analytics, which alerts patients to "Urgent Low Soon" scenarios, has made these devices indispensable for pediatric and elderly patients, who are most vulnerable to nocturnal hypoglycemia.

• By End-User: Home Care

The Home Care segment is the dominant end-user category, representing a shift away from hospital-centric monitoring toward self-managed digital health. This requirement is propelled by the proliferation of smartphone-compatible CGM apps that enable "remote following." This feature is particularly valuable in South America, where family-led care is culturally prevalent; it allows caregivers to monitor a patient’s glucose levels in real-time from a separate location. The expansion of Direct-to-Consumer (DTC) e-commerce channels by manufacturers like Dexcom and Abbott has further fueled this segment, bypassing traditional pharmacy bottlenecks. In 2025, the demand for home-based CGM is also being supported by private health insurance providers in Brazil and Chile, who have begun to recognize that the cost of providing a CGM sensor is significantly lower than the cost of an emergency room visit for a diabetic ketoacidosis (DKA) episode.

South America Continuous Glucose Monitoring Market Geographical Analysis

• Brazil Market Analysis

Brazil is the cornerstone of the South American CGM market, driven by its large population and established regulatory framework. Its necessity is focused on the FreeStyle Libre and Medtronic MiniMed ecosystems. A key local factor impacting demand is the presence of the SUS (Sistema Único de Saúde); while universal coverage for CGM is not yet fully implemented, judicial mandates often require the state to provide these devices to Type 1 patients, creating a "top-down" demand pressure on the public health budget.

• Argentina Market Analysis

The Argentine market is characterized by high clinical awareness and a strong preference for advanced technology. The recent launch of Dexcom ONE in Argentina marked the company’s first significant entry into Latin America, addressing a demand for high-accuracy, real-time alerts. Despite macroeconomic volatility, the demand for CGM remains resilient in the private sector (Obras Sociales), where high-income patients prioritize glycemic variability management to maintain quality of life.

South America Continuous Glucose Monitoring Market Competitive Environment and Analysis

The competitive landscape is defined by a "Big Three" dominance, including Abbott, Dexcom, and Medtronic, though the market is bracing for a shift as Medtronic restructures its operations.

• Abbott Laboratories

Abbott is the volume leader in South America, primarily through its FreeStyle Libre platform. Its strategic positioning is built on affordability and accessibility. Abbott’s strategy involves aggressive pricing, often matching the cost of traditional test strips, to enable mass-market adoption. In 2024, Abbott expanded its portfolio with the launch of the Lingo sensor in the U.S., a technology expected to eventually transition to international markets to target the "health and wellness" consumer segment, further broadening its demand base beyond clinical diabetes.

• DexCom, Inc.

Dexcom is positioned as the "premium accuracy" leader. Its strategy focuses on high-performance sensing and seamless connectivity with third-party AID systems like the Tandem t:slim X2 and Insulet Omnipod 5. The 2023 launch of Dexcom ONE in Argentina was a pivotal strategic move to offer a more affordable version of its core technology to the South American market. In late 2025, Dexcom launched the G7 15-day sensor in the U.S., a development that sets a new benchmark for wear-time that the company will likely leverage to capture market share from competitors in the South American "convenience" segment.

• Medtronic plc (Diabetes Group)

Medtronic focuses on the integrated ecosystem, catering to patients who require intensive insulin management. Its MiniMed 780G system, which uses the Guardian 4 sensor, is a market leader in the closed-loop segment. A major strategic development occurred in May 2025 with the announcement of the intent to spin off the Diabetes business into "MiniMed." This new entity will be the only company with a complete ecosystem (CGM + Pump + Algorithm) under one roof, positioning it to provide a highly differentiated, data-driven "artificial pancreas" solution to the South American market.

South America Continuous Glucose Monitoring Market Developments

• December 2025: Abbott announced the expansion of its Lingo biowearable to Android users, significantly broadening the potential user base for its real-time glucose sensing technology across diverse global smartphone demographics.
• November 2025: DexCom, Inc. announced the official launch of the Dexcom G7 15 Day system in the US, providing 15.5 days of wear-time and enhancing the convenience and environmental sustainability of its glucose biosensing technology.
• September 2025: Medtronic plc achieved a major regulatory milestone with the FDA clearance of the MiniMed 780G system to integrate with the Instinct sensor, a CGM manufactured by Abbott, facilitating greater interoperability between leading platforms.

South America Continuous Glucose Monitoring Market Segmentation

By Application

• Diabetes Patients
• Critical Patients

By End-User Industry

• Hospitals
• Diagnostic Centers & Clinics
• Home Care

By Country

• Brazil
• Argentina
• Others

Table Of Contents

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. SOUTH AMERICA CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients

6. SOUTH AMERICA CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

7.  SOUTH AMERICA CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY COUNTRY

7.1. Introduction

7.2. Brazil

7.3. Argentina

7.4. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES 

9.1. Abbott Laboratories

9.2. Dexcom, Inc.

9.3. Medtronic plc

9.4. Senseonics Holdings, Inc.

9.5. Insulet Corporation

9.6. Roche Holding AG

9.7. Ypsomed AG

9.8. GlySens Incorporated

9.9. Tandem Diabetes Care, Inc.

9.10. Nemaura Medical Inc.

Companies Profiled

Abbott Laboratories

Dexcom, Inc.

Medtronic plc

Senseonics Holdings, Inc.

Insulet Corporation

Roche Holding AG

Ypsomed AG

GlySens Incorporated

Tandem Diabetes Care, Inc.

Nemaura Medical Inc.

Related Reports